Theravance Biopharma Phase 3 Fail Spurs Strategic Review, $70M Annual Cost Cuts
Theravance Biopharma's Phase 3 CYPRESS study of ampreloxetine in nOH failed its OHSA composite score primary endpoint, triggering program wind-down and an accelerated strategic review. The company will cut operating expenses by 60%—saving about $70 million annually—focus on YUPELRI® and hold roughly $400 million cash by end Q1 2026.
1. Phase 3 CYPRESS Study Failure
The Phase 3 CYPRESS trial of ampreloxetine in patients with symptomatic neurogenic orthostatic hypotension did not achieve statistical significance on the OHSA composite score primary endpoint, leading Theravance Biopharma to discontinue the ampreloxetine program.
2. Strategic Review Committee Actions
The board’s Strategic Review Committee has accelerated its comprehensive evaluation of value-maximizing alternatives, including potential sale or other transactions, with no assurance of a definitive outcome.
3. Organizational Restructuring and Cost Reductions
The company will restructure by winding down its R&D function, reducing G&A expenses and slashing operating costs by 60%, targeting approximately $70 million in annual savings fully materializing by Q3 2026.
4. Financial Position and Commercial Focus
Theravance expects roughly $400 million in cash by end Q1 2026, supports a streamlined portfolio centered on YUPELRI® (FY 2025 net sales $266.6 million), and anticipates a $100 million TRELEGY milestone payment in 2026.